Meanwhile, Kidney Disease: Improving Global Outcomes (KDIGO) guidelines stress individualized reno-protective strategies, including RAAS blockade (using ACE inhibitors or angiotensin receptor blockers) and SGLT2 inhibitors to reduce CKD progression and cardiovascular risk [214]. Here, SLC5A2 is linked to kidney disorder.